147 related articles for article (PubMed ID: 17220537)
1. Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'.
Dabek J; Kułach A; Monastyrska-Cup B; Gasior Z
Pharmacol Rep; 2006; 58(6):799-805. PubMed ID: 17220537
[TBL] [Abstract][Full Text] [Related]
2. TGF-β and restenosis revisited: a Smad link.
Suwanabol PA; Kent KC; Liu B
J Surg Res; 2011 May; 167(2):287-97. PubMed ID: 21324395
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta, cell signaling and cardiovascular disorders.
Agrotis A; Kalinina N; Bobik A
Curr Vasc Pharmacol; 2005 Jan; 3(1):55-61. PubMed ID: 15638782
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta: a promising target for anti-stenosis therapy.
Chamberlain J
Cardiovasc Drug Rev; 2001; 19(4):329-44. PubMed ID: 11830751
[TBL] [Abstract][Full Text] [Related]
5. Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists.
Deng YL; Xiong XZ; Cheng NS
Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):467-78. PubMed ID: 23060391
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis.
Grainger DJ
Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):399-404. PubMed ID: 14699019
[TBL] [Abstract][Full Text] [Related]
7. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting.
Ward MR; Agrotis A; Kanellakis P; Hall J; Jennings G; Bobik A
Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):940-8. PubMed ID: 12067902
[TBL] [Abstract][Full Text] [Related]
8. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.
Edgley AJ; Krum H; Kelly DJ
Cardiovasc Ther; 2012 Feb; 30(1):e30-40. PubMed ID: 21883991
[TBL] [Abstract][Full Text] [Related]
9. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions.
Santibañez JF; Quintanilla M; Bernabeu C
Clin Sci (Lond); 2011 Sep; 121(6):233-51. PubMed ID: 21615335
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of protein tyrosine kinases attenuates increases in expression of transforming growth factor-beta isoforms and their receptors following arterial injury.
Ward MR; Agrotis A; Kanellakis P; Dilley R; Jennings G; Bobik A
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2461-70. PubMed ID: 9409216
[TBL] [Abstract][Full Text] [Related]
11. A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension.
Yung LM; Nikolic I; Paskin-Flerlage SD; Pearsall RS; Kumar R; Yu PB
Am J Respir Crit Care Med; 2016 Nov; 194(9):1140-1151. PubMed ID: 27115515
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty.
Kingston PA; Sinha S; Appleby CE; David A; Verakis T; Castro MG; Lowenstein PR; Heagerty AM
Circulation; 2003 Dec; 108(22):2819-25. PubMed ID: 14638551
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition.
Kingston PA; Sinha S; David A; Castro MG; Lowenstein PR; Heagerty AM
Circulation; 2001 Nov; 104(21):2595-601. PubMed ID: 11714656
[TBL] [Abstract][Full Text] [Related]
14. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.
Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY
Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614
[TBL] [Abstract][Full Text] [Related]
15. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.
Kapoun AM; Liang F; O'Young G; Damm DL; Quon D; White RT; Munson K; Lam A; Schreiner GF; Protter AA
Circ Res; 2004 Mar; 94(4):453-61. PubMed ID: 14726474
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression.
Lutgens E; Gijbels M; Smook M; Heeringa P; Gotwals P; Koteliansky VE; Daemen MJ
Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):975-82. PubMed ID: 12067907
[TBL] [Abstract][Full Text] [Related]
17. Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury.
Kobayashi K; Yokote K; Fujimoto M; Yamashita K; Sakamoto A; Kitahara M; Kawamura H; Maezawa Y; Asaumi S; Tokuhisa T; Mori S; Saito Y
Circ Res; 2005 Apr; 96(8):904-12. PubMed ID: 15790953
[TBL] [Abstract][Full Text] [Related]
18. Impact of cytokine gene polymorphism on cardiovascular risk in renal transplant recipients.
Altun B; Yilmaz R; Kahraman S; Gençtoy G; Arici M; Onalan O; Oto A; Hayran M; Bakkaloğlu M; Yasavul U; Turgan C
Transpl Int; 2005 Jun; 18(6):681-9. PubMed ID: 15910294
[TBL] [Abstract][Full Text] [Related]
19. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth.
Smith JD; Bryant SR; Couper LL; Vary CP; Gotwals PJ; Koteliansky VE; Lindner V
Circ Res; 1999 May; 84(10):1212-22. PubMed ID: 10347096
[TBL] [Abstract][Full Text] [Related]
20. The role of Smad3-dependent TGF-beta signal in vascular response to injury.
Yokote K; Kobayashi K; Saito Y
Trends Cardiovasc Med; 2006 Oct; 16(7):240-5. PubMed ID: 16980181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
